Akari enrols seven out of nine patients in bullous pemphigoid trial
Akari Therapeutics’ Phase II trial investigating Coversin (nomacopan) in mild-to-moderate bullous pemphigoid has so far enrolled seven out of its...
Trending menu:
-
![Cassiopea’s Winlevi uptake in acne driven by new mechanism though interest to wane]()
Cassiopea’s Winlevi uptake in acne driven by new mechanism though interest to wane
-
![AstraZeneca’s Imfinzi falls at another hurdle in non-small cell lung cancer trial]()
AstraZeneca’s Imfinzi falls at another hurdle in non-small cell lung cancer trial
-
![The most researched drugs in cystic fibrosis trials]()
The most researched drugs in cystic fibrosis trials
-
![Improved clinical efficacy found wanting in Phase III IMPALA trial]()
Improved clinical efficacy found wanting in Phase III IMPALA trial
-
![New, efficacious options offer hope for Ebola treatment and containment]()
New, efficacious options offer hope for Ebola treatment and containment
-
![GSK’s Zejula meets primary goal in Phase III ovarian cancer trial]()
GSK’s Zejula meets primary goal in Phase III ovarian cancer trial
Expert commentary & analysis from GlobalData
New positive data presented for Janssen’s ponesimod remains questionable
Chasing Cancer considers how to improve patient access to cancer therapies
First-in-class HIF-2a inhibitor could revolutionise renal cell carcinoma treatment algorithm
Trial halted early as Nuplazid shows strong efficacy in dementia-related psychosis
Most Read
Company releases
Industry Leaders Come on Board as NMiTE Adds Engineering Expertise
The New Model in Technology and Engineering (NMiTE) has announced three appointments to its Board of Trustees.
Inocure at Electrospin, China
See Malvern Panalytical’s Upcoming Webinars
Malvern Panalytical has announced its next round of webinars. Find out more below. If you are interested in attending any...
Pfanstiehl to Attend Two Events in August
Almac Group Launches Almac Adapt: A New Patient-centric Supply Solution
Almac Clinical Services has announced the launch of Almac Adapt, an innovative Just in Time...
Company whitepapers
Primary Cells Isolated from Healthy Human and Animal Tissues
Caltag MedsystemsStudy: Comparing Efficacy and Tolerability of New Daily Oral Vitamin B12 and Intermittent Intramuscular Vitamin B12
Emisphere TechnologiesSTZ-Induced Rat Model of Diabetes
Noble Life SciencesUnderstanding Sucrose: Matching Sucrose Quality to Functional Need
PfanstiehlClinical Trials: Gene Therapy
GlobalDataClinical Trials: A Round-Up of 2018
GlobalDataProtein Sciences Platform
NEOMED-LABSCompany A-Z
Clinical Trials
Biogen to study higher dose of Spinraza in SMA
Biogen has announced plans to evaluate a higher dose of its spinal muscular atrophy (SMA) drug Spinraza (nusinersen) in a new Phase II/III clinical trial...
Cosentyx meets Phase III goals in axial spondyloarthritis patients
Trial evaluates senolytic drugs to treat kidney disease
Novo Nordisk reports positive data for oral semaglutide
Poxel begins new study of NASH candidate PXL065
Drug Development
Biogen to study higher dose of Spinraza in SMA
Biogen has announced plans to evaluate a higher dose of its spinal muscular atrophy (SMA) drug Spinraza (nusinersen) in a new Phase II/III clinical trial...
Cosentyx meets Phase III goals in axial spondyloarthritis patients
Novo Nordisk reports positive data for oral semaglutide
Cassava Sciences to assess Alzheimer’s drug in Phase IIb trial
Novartis’ Phase III studies of ofatumumab achieve primary goals
Go Top